Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris

Next Previous
X
Search
Trial Profile

An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Mar 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dapsone (Primary)
  • Indications Acne vulgaris
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Allergan

    • Most Recent Events

    • 10 Sep 2019 According to an Almirall media release, based on the data from thsi study, the FDA has approved Aczone 7.5% Gel , for the expanded indication to include patients aged 9-11 for the topical treatment of Acne vulgaris.
    • 11 Jun 2018 Status changed from recruiting to completed.
    • 11 Nov 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top